SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is trending following preliminary positive clinical data for its GLSI-100 immunotherapy, showing an 80% reduction in breast cancer recurrence rates. This, combined with the company's board extending insider share lock-ups until 2026, signals strong confidence and is fueling fervent community discussion around a potential short squeeze, given the extremely high cost to borrow and limited available shares.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano ($ADA) is currently a hotbed of intense community FUD, with many investors vehemently labeling it a 'scam' and predicting significant 'rugpulls' and 'dumps,' largely blaming its founder Charles Hoskinson. Despite widespread bearish sentiment suggesting the project is 'dead,' a smaller segment is actively accumulating, anticipating a future market resurgence or positive legislative impact like a 'Clarity Act' run. The pervasive negative sentiment, fueled by perceived price underperformance, is the immediate catalyst driving conversation around $ADA.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust (SLV) is experiencing intense trading activity amidst a sharp price pullback, largely attributed to increased margin requirements by a major commodities exchange triggering forced liquidations. Investors are fiercely debating whether this represents a "buy the dip" opportunity, fueled by concerns over looming export restrictions from a key global consumer and persistent supply/demand imbalances, or if it signals an unsustainable top after a parabolic ascent. This market action underscores the deep divide between perceived paper market manipulation and the fundamental outlook for physical silver.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital is trending amidst significant year-end tax-loss harvesting, with the community expressing widespread frustration over its notable underperformance and perceived management issues, particularly regarding share dilution. Despite the stock trading at a discount to its Bitcoin holdings, proponents highlight its strategic pivot into AI/HPC data centers and substantial short interest as potential catalysts for a rebound.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical is trending after its setrusumab drug for osteogenesis imperfecta failed to meet primary endpoints in late-stage trials, prompting a significant stock decline. The community is actively debating whether this represents an overreaction, pointing to the company's existing approved products and deep pipeline as reasons for a potential rebound.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending due to robust demand for AI-driven memory solutions, with reports indicating rising HBM prices and a strong outlook for supply shortages extending into 2026. The community is actively discussing Micron's perceived undervaluation despite its impressive growth and leadership in the critical AI memory sector, while some express caution about the rapid ascent. This narrative has led to a highly bullish sentiment, with many anticipating continued strength as memory becomes a crucial constraint and differentiator in modern AI systems.

TryHard Holdings Ltd. is a lifestyle entertainment company that operates in Japan offering a diverse range of services across the entertainment and hospitality sectors. It operates through the following business segments: Consultancy and management, Event curation, Sub-leasing and Restaurants. The Consultancy and management segment provides expert services to clubs, including operations, event management, and strategic support to enhance performance and engagement. The Event curation segment organize and produce own events, also provides a full suite of services, including event planning, construction, entertainment booking, event operation, and ticket sales. The Sub-Leasing segment acts as an intermediary between landlords and clubs. The Restaurants segment operates several restaurants. The company was founded on October 16, 2013 and is headquartered in Osaka, Japan.

TryHard Holdings Ltd.

TryHard Holdings Ltd. ($THH) is a top trending stock following its recent Initial Public Offering (IPO) on NASDAQ, with community discussion centered on its high volatility as a low-float play. While some investors are optimistic about its significant price appreciation potential, others are highly skeptical, raising concerns about its dramatic price swings and labeling it as a potential "pump and dump."

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is drawing significant attention with upcoming CES 2026 as a potential catalyst for new partnerships, alongside recent analyst upgrades pointing to its leading voice AI technology. While many investors highlight the company's strong fundamentals, including a substantial contractual backlog and no debt, community dialogue is split between optimism for a rebound and concerns over recent insider selling.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending due to a series of positive regulatory updates and clinical trial results, with community speculation centered on its undervalued status and significant pipeline potential. Recent highlights include a favorable appeals court ruling on Hetlioz for jet lag and promising data for tradipitant in mitigating GLP-1 induced nausea, which could unlock a massive market. Traders are actively discussing multiple upcoming regulatory decisions and potential acquisition interest, positioning the stock for a pivotal period.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is currently capturing significant attention, driven by enthusiastic discussions around the impending LitVM airdrop and the launch of its Omnichain system, which introduces new yield-earning capabilities. The community is actively debating strong bullish prospects and favorable technical indicators, reinforcing its long-held narrative as "digital silver" within the broader crypto market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Detailed Fundamental Analysis - XLV

Below is Validea's ETF fundamental report for SPDR Health Care Select Sector SPDR Fund (XLV). The report looks at XLV's exposure to the major investing factors including value, quality, momentum and...

 Bet on These Top-Ranked Healthcare ETFs Before 2025 Ends

XLV and similar healthcare ETFs are gaining momentum as strength in biotech, increased AI adoption, and rising defensive demand position the sector for year-end leadership. 

<ul class="summary-bullets"><li>MFN pricing extended nationwide through Medicaid and to future new medicines.</li><li>Steep direct-to-patient discounts rolled out via TrumpRx, including $35 insulin.</li><li>Additional pharma companies, including Johnson &amp; Johnson, are expected to ink similar deals next week.</li></ul><p>U.S. President Donald Trump on Friday announced nine new agreements with pharmaceutical companies to lower prescription drug prices for Americans to the lowest levels paid in other developed nations, under what the administration calls a “most-favored-nation” (MFN) pricing framework.</p><p>With these additions, 14 of the 17 pharmaceutical companies targeted by the administration in August have now signed on.</p><h2 class="st-heading-2"><strong>Big Pharma Roster Expands</strong></h2><p>The companies named in Friday’s agreements are Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis and Sanofi.</p><p>Trump said additional companies, including Johnson &amp; Johnson, are expected to announce similar agreements next week, as the administration continues to expand the program.</p><h2 class="st-heading-2"><strong>Medicaid Savings And Future Drug Pricing</strong></h2><p>The White House said the agreements apply to drugs used to treat an array of expensive, long-term conditions including type two diabetes, rheumatoid arthritis, multiple sclerosis, asthma, chronic obstructive pulmonary disease, hepatitis B and C, HIV and certain cancers.</p><p>The administration said every state Medicaid program in the U.S. will benefit from MFN prices on products from the nine companies, which it estimates will save billions of dollars. The agreements also require MFN pricing for all new innovative medicines these companies bring to market.</p><p>Trump also floated the idea of calling a meeting with insurance companies to discuss further ways to lower healthcare costs, suggesting insurers could significantly reduce prices or face alternative approaches that would direct savings to consumers.</p><h2 class="st-heading-2"><strong>Deep Discounts Via TrumpRx</strong></h2><p>The administration said the companies are required to offer medicines at steep discounts off list prices when selling directly to American patients through TrumpRx, a government-backed direct-to-patient drug purchasing platform.</p><p>The administration said patients would see steep price cuts, citing examples such as Amgen’s Repatha at $239 versus&nbsp;list price of $573, Bristol Myers Squibb’s Reyataz at $217 versus $1,449, and Sanofi’s Plavix at $16 versus $756, alongside similar reductions for drugs from Gilead, GSK, Merck and Novartis. The administration also said Sanofi will list its insulin products on TrumpRx at $35&nbsp;for every&nbsp;month’s supply.</p><h2 class="st-heading-2"><strong>Drugmakers Pledge Domestic Investment</strong></h2><p>Trump said the participating companies have committed to invest at least $150 billion collectively in U.S. pharmaceutical manufacturing in the near term.</p><p>The administration also said several companies will donate active pharmaceutical ingredients to the Strategic Active Pharmaceutical Ingredients Reserve to strengthen emergency preparedness. GSK will contribute 98.8 kg of Albuterol, Bristol Myers Squibb will contribute tablets representing 6.5 tons of Apixaban, and Merck will contribute 3.5 tons of Ertapenem.</p><h2 class="st-heading-2"><strong>How Did Stocktwits React?</strong></h2><p>On Stocktwits, Health Care Select Sector SPDR Fund (XLV) showed 'bearish' retail sentiment amid 'high' message volume, while iShares Global Healthcare ETF (IXJ) saw 'bullish' sentiment with 'high' activity.</p><p><a href="https://stocktwits.com/symbol/XLV">XLV</a> and&nbsp;<a href="https://stocktwits.com/symbol/IXJ">IXJ</a> have risen 14% so far this year.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Trump announced his plan to lower drug prices would tie their cost to drug prices paid in foreign nations. (Photo by Andrew Harnik/Getty Images)

Trump Locks In Drug-Price Cuts With Roche, Novartis, Merck — More Big Pharma Deals Coming Next Week

The deals expand the pricing program to several drugmakers in exchange for temporary tariff relief.

Equity

Why Wall Street May Remain Bullish in 2026? ETFs in Focus 

Wall Street eyes a bullish 2026 as GDP looks likely to accelerate, AI mania continues and earnings solidify. ETFs like RSP, XLV and XSW come into focus. 

Should You Invest in the State Street Health Care Select Sector SPDR ETF ETF (XLV)?

Fed Watch: Will Jerome Powell Goose the Stock Market?

Healthcare and Energy stocks have perked up ahead of this meeting--should investors favor defensive positioning going forward?

Top-Ranked ETFs to Power Your Portfolio Higher 

With market tailwinds building and optimism returning, these top-ranked ETFs can help investors capture momentum safely.

Best-Performing ETFs of November 

November muted for markets, but ETFs like SPYM, BWET, WNTR, LITP and OZEM stand out.

Is Dow Jones ETF Better-Placed Than S&P 500 & Nasdaq?

The Dow Jones ETF DIA may outperform SPY and QQQ as rate-cut hopes rise, tech volatility lingers and defensive sectors strengthen.

The Zacks Analyst Blog SPDR Gold Trust, HDGE, PGHY and XLV

GLD gains attention as AI bubble fears rise, with investors eyeing hedges and ETFs geared toward market downside protection.

XLV
Health Care Select Sector SPDR Fund

Feed

News

Sentiment

Fundamentals

Info

Latest XLV News

XLVHealth Care Select Sector SPDR Fund